Biopharma's focus on rare conditions and financial reward, exemplified:
A rare disease—primary AATR cardiac amyloidosis—is the subject of an emerging 3-way treatment competition for many $ billions per year. https://
wsj.com/health/pharma/
the-brawl-taking-shape-over-pfizers-multibillion-dollar-heart-monopoly-43a220c2?mod=Searchresults_pos1&page=1
… @pfizer @BridgeBioPharma @Alnylam

→ View original post on X — @erictopol,